Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
3.650
-0.490 (-11.84%)
Oct 13, 2026, 2:51 PM EDT - Market open
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $5.49M in the twelve months ending June 30, 2026, down -32.27% year-over-year. In the year 2025, Taysha Gene Therapies had annual revenue of $9.77M with 17.28% growth. That makes Taysha Gene Therapies the 39,618th largest company in the world by revenue and 5,261st in the United States.
Revenue (ttm)
$5.49M
Revenue Growth
-32.27%
P/S Ratio
245.93
Revenue / Employee
$55,404
Employees
99
Market Cap
1.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.77M | 1.44M | 17.28% |
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 717.00M |
| Immunocore Holdings | 430.78M |
| Syndax Pharmaceuticals | 252.25M |
| Nektar Therapeutics | 54.59M |
| Omeros | 38.42M |
| Maze Therapeutics | 20.00M |
| Inhibrx Biosciences | 1.30M |
TSHA News
- 11 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting - GlobeNewsWire
- 26 days ago - Taysha Gene Therapies initiated with an Outperform at Wolfe Research - TheFly
- 2 months ago - Taysha Gene Therapies Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Taysha Gene Therapies Earnings release: Q2 2026 - Filings
- 2 months ago - Taysha Gene Therapies Quarterly report: Q2 2026 - Filings
- 2 months ago - Taysha Gene Therapies reports Q2 EPS (13c), consensus (11c) - TheFly
- 2 months ago - Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire